Cargando…
Clinical experience with pegaptanib sodium
Pegaptanib sodium (Macugen(®)) blocks the extracellular vascular endothelial growth factor (VEGF) isoform VEGF(165), whose elevated levels are associated with the development of choroidal neovascularization (CNV). This selective inhibition prevents binding to the VEGF receptors and the development o...
Autores principales: | Rosina, Chiara, Bottoni, Ferdinando, Staurenghi, Giovanni |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694030/ https://www.ncbi.nlm.nih.gov/pubmed/19668746 |
Ejemplares similares
-
Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK
por: Sivaprasad, Sobha, et al.
Publicado: (2008) -
Pegaptanib sodium for ocular vascular disease
por: Shukla, Dhananjay, et al.
Publicado: (2007) -
Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema
por: Querques, G., et al.
Publicado: (2009) -
Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany
por: Feucht, Nikolaus, et al.
Publicado: (2008) -
Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration
por: Sivaprasad, Sobha
Publicado: (2008)